UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025. The company ...

Clinigen has appointed Nihad Hasagic as Senior Vice President for Clinigen Lifecycle Services (SVP CLS). CLS plays a key role in Clinigen’s growing service portfolio, helping to facilitate accelerated ...

Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic ...

The PharmaTimes Clinical Researcher of the Year – The Americas 2025 Awards offer an unparalleled opportunity to showcase your ...

Tozaro has announced the appointment of Dr Jason Slingsb y as Chief Executive Officer. Jason will lead the company’s ...

Santen has announced that the European Commission has granted market authorisation for Ryjunea, a low-dose atropine eye drop ...

Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test for sexually transmitted infections ...

Sogroya acts as a replacement for endogenous growth hormone and is administered once a week to support growth in children ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines ...

Flip feasibility: from capacity and capability to human realities True feasibility begins with understanding the patient.

The National Institute for Health and Care Excellence (NICE) has published updated guidance recommending Forxiga ...